|
1
|
Lafaro KJ, Demirjian AN and Pawlik TM:
Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am.
24:1–17. 2015. View Article : Google Scholar
|
|
2
|
Stewart BW and Wild CP: World Cancer
Report 2014. IARC; Nonserial Publication: 2014
|
|
3
|
Nordenstedt H, White DL and El-Serag HB:
The changing pattern of epidemiology in hepatocellular carcinoma.
Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB and Kanwal F: Epidemiology of
hepatocellular carcinoma in the United States: Where are we? Where
do we go? Hepatology. 60:1767–1775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kew MC and Kew MC: Hepatocellular
carcinoma: Epidemiology and risk factors. J Hepa Carc. 1:115–125.
2014.
|
|
6
|
Chakraborty AK and Pawelek JM: GnT-V,
macrophage and cancer metastasis: A common link. Clin Exp
Metastasis. 20:365–373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song K, Ko JH and Kim YS: Role of
N-acetylglucosaminyltra nsferase-V and galectin-3 binding protein
in anoikis stress of cancer cells (788.1). FASEB J. 28:781–788.
2014.
|
|
8
|
Murata K, Miyoshi E, Kameyama M, Ishikawa
O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S,
et al: Expression of N-acetylglucosaminyltransferase V in
colorectal cancer correlates with metastasis and poor prognosis.
Clin Cancer Res. 6:1772–1777. 2000.PubMed/NCBI
|
|
9
|
Handerson T, Camp R, Harigopal M, Rimm D
and Pawelek J: β1, 6-branched oligosaccharides are increased in
lymph node metastases and predict poor outcome in breast carcinoma.
Clin Cancer Res. 11:2969–2973. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takahashi N, Yamamoto E, Ino K, Miyoshi E,
Nagasaka T, Kajiyama H, Shibata K, Nawa A and Kikkawa F: High
expression of N-acetylglucosaminyltransferase V in mucinous tumors
of the ovary. Oncol Rep. 22:1027–1032. 2009.PubMed/NCBI
|
|
11
|
Huang B, Sun L, Cao J, Zhang Y, Wu Q,
Zhang J, Ge Y, Fu L and Wang Z: Downregulation of the GnT-V gene
inhibits metastasis and invasion of BGC823 gastric cancer cells.
Oncol Rep. 29:2392–2400. 2013.PubMed/NCBI
|
|
12
|
Seto K, Uchida F, Baba O, Yamatoji M,
Karube R, Warabi E, Sakai S, Hasegawa S, Yamagata K, Yanagawa T, et
al: Negative expression of N-acetylglucosaminyltransferase V in
oral squamous cell carcinoma correlates with poor prognosis.
Springerplus. 2:6572013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang H, Chen W, Liu Q, Wei T, Zhu W, Meng
H, Guo L and Zhang J: Inhibition of N-acetylglucosaminyltransferase
V enhances sensitivity of radiotherapy in human prostate cancer.
Biochem Biophys Res Commun. 451:345–351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo HB, Liu F, Zhao JH and Chen HL:
Down-regulation of N-acetylglucosaminyltransferase V by
tumorigenesis- or metastasis-suppressor gene and its relation to
metastatic potential of human hepatocarcinoma cells. J Cell
Biochem. 79:370–385. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taniguchi N, Ihara S, Saito T, Miyoshi E,
Ikeda Y and Honke K: Implication of GnT-V in cancer metastasis: A
glycomic approach for identification of a target protein and its
unique function as an angiogenic cofactor. Glycoconj J. 18:859–865.
2001. View Article : Google Scholar
|
|
16
|
Yang JY, Luo HY, Lin QY, Liu ZM, Yan LN,
Lin P, Zhang J and Lei S: Subcellular daunorubicin distribution and
its relation to multidrug resistance phenotype in drug-resistant
cell line SMMC-7721/R. World J Gastroenterol. 8:644–649. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li GP, Chen XP and Ye L: The role of BCRP
in hepatocellular carcinoma multidrug resistance and mechanism. J
Abdom Surg. 5:242006.
|
|
18
|
Albermann N, Schmitz-Winnenthal FH,
Z'graggen K, Volk C, Hoffmann MM, Haefeli WE and Weiss J:
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1,
MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear
cells and their relationship with the expression in intestine and
liver. Biochem Pharmacol. 70:949–958. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yanagi M, Aoyagi Y, Suda T, Mita Y and
Asakura H: N-Acetylglucosaminyltransferase V as a possible aid for
the evaluation of tumor invasiveness in patients with
hepatocellular carcinoma. J Gastroenterol Hepatol. 16:1282–1289.
2001. View Article : Google Scholar
|
|
20
|
Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh
T, Katoh H and Taniguchi N: Expression of
N-acetylglucosaminyltransferase v is associated with prognosis and
histology in non-small cell lung cancers. Clin Cancer Res.
10:1773–1779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo P, Chen HJ, Wang QY and Chen HL: Down
regulation of N-acetylglucosaminyltransferase V facilitates
all-transretinoic acid to induce apoptosis of human hepatocarcinoma
cells. Mol Cell Biochem. 284:103–110. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyoshi E, Terao M and Kamada Y:
Physiological roles of N-ac etylglucosaminyltransferase V (GnT-V)
in mice. BMB Rep. 45:554–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicholson DW: Caspase structure,
proteolytic substrates, and function during apoptotic cell death.
Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Beerheide W, Tan YJ, Teng E, Ting AE,
Jedpiyawongse A and Srivatanakul P: Downregulation of proapoptotic
proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular
carcinomas. Biochem Biophys Res Commun. 273:54–61. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deng B, Zhang XF, Zhu XC, Huang H, Jia HL,
Ye QH, Dong QZ and Qin LX: Correlation and prognostic value of
osteopontin and Bcl-2 in hepatocellular carcinoma patients after
curative resection. Oncol Rep. 30:2795–2803. 2013.PubMed/NCBI
|
|
26
|
Stetler-Stevenson WG, Aznavoorian S and
Liotta LA: Tumor cell interactions with the extracellular matrix
during invasion and metastasis. Annu Rev Cell Biol. 9:541–573.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmalfeldt B, Prechtel D, Härting K,
Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W,
et al: Increased expression of matrix metalloproteinases (MMP)-2,
MMP-9, and the urokinase-type plasminogen activator is associated
with progression from benign to advanced ovarian cancer. Clin
Cancer Res. 7:2396–2404. 2001.PubMed/NCBI
|
|
28
|
Karahan N, Güney M, Baspinar S, Oral B,
Kapucuoglu N and Mungan T: Expression of gelatinase (MMP-2 and
MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J
Gynaecol Oncol. 28:184–188. 2007.PubMed/NCBI
|
|
29
|
Määttä M, Soini Y, Liakka A and
Autio-Harmainen H: Differential expression of matrix
metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in
hepatocellular and pancreatic adenocarcinoma: Implications for
tumor progression and clinical prognosis. Clin Cancer Res.
6:2726–2734. 2000.PubMed/NCBI
|
|
30
|
Arii S, Mise M, Harada T, Furutani M,
Ishigami S, Niwano M, Mizumoto M, Fukumoto M and Imamura M:
Overexpression of matrix metalloproteinase 9 gene in hepatocellular
carcinoma with invasive potential. Hepatology. 24:316–322. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dean M, Hamon Y and Chimini G: The human
ATP-binding cassette (ABC) transporter superfamily. J Lipid Res.
42:1007–1017. 2001.PubMed/NCBI
|
|
32
|
Gillet JP, Efferth T and Remacle J:
Chemotherapy-induced resistance by ATP-binding cassette transporter
genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
|
|
33
|
Haimeur A, Conseil G, Deeley RG and Cole
SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins:
Biology, substrate specificity and regulation. Curr Drug Metab.
5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leslie EM, Deeley RG and Cole SP:
Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2,
and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol.
204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maliepaard M, van Gastelen MA, de Jong LA,
Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and
Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a
topotecan-selected ovarian tumor cell line. Cancer Res.
59:4559–4563. 1999.PubMed/NCBI
|
|
37
|
Robey RW, Medina-Pérez WY, Nishiyama K,
Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates
SE: Overexpression of the ATP-binding cassette half-transporter,
ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast
cancer cells. Clin Cancer Res. 7:145–152. 2001.PubMed/NCBI
|
|
38
|
Duan Z, Brakora KA and Seiden MV:
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small
interfering RNA and reversal of paclitaxel resistance in human
ovarian cancer cells. Mol Cancer Ther. 3:833–838. 2004.PubMed/NCBI
|
|
39
|
Sukowati CH, Rosso N, Pascut D, Anfuso B,
Torre G, Francalanci P, Crocè LS and Tiribelli C: Gene and
functional up-regulation of the BCRP/ABCG2 transporter in
hepatocellular carcinoma. BMC Gastroenterol. 12:1602012. View Article : Google Scholar : PubMed/NCBI
|
